Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Revenues:
Product	$ 81	$ 134
License	158	176
Contract research and government grants	576	1,067
Total revenues (which includes $23 and $23 from related parties - Note 8)	815	1,377
Operating expenses:
Cost of product revenues	56	91
Research and development	1,832	1,983
Selling, general and administrative	2,638	1,885
Total operating expenses	4,526	3,959
Loss from operations	(3,711)	(2,582)
Interest expense	(467)	(384)
Other expense, net	(1,396)	(21)
Net loss before income taxes and equity in loss of unconsolidated entity	(5,574)	(2,987)
Income tax provision	(229)	(93)
Equity in loss of unconsolidated entity		(396)
Net loss and comprehensive loss	(5,803)	(3,476)
Accretion of redeemable convertible preferred stock to redemption value	(1,695)
Deemed dividend to warrant holder	(197)
Net loss attributable to common stockholders	$ (7,695)	$ (3,476)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (3.71)	$ (1.69)
Weighted-average number of shares used in per share calculations:
Basic and diluted	2,075,407	2,056,559